The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Aquestive Therapeutics's share price is $4.07.
Aquestive Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.78. Hence, Aquestive Therapeutics's PS Ratio for today is 5.22.
The historical rank and industry rank for Aquestive Therapeutics's PS Ratio or its related term are showing as below:
AQST'
s PS Ratio Range Over the Past 10 Years
Min: 0.52 Med: 2.48 Max: 7.82
Current: 5.22
During the past 8 years, Aquestive Therapeutics's highest PS Ratio was 7.82. The lowest was 0.52. And the median was 2.48.
AQST's PS Ratio is ranked worse than 79.86% of 1003
companies
in the Drug Manufacturers industry
Industry Median: 2.16
vs AQST: 5.22
Aquestive Therapeutics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Aquestive Therapeutics was -15.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -15.40% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -23.00% per year.
During the past 8 years, Aquestive Therapeutics's highest 3-Year average Revenue per Share Growth Rate was -0.60% per year. The lowest was -25.90% per year. And the median was -22.20% per year.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Aquestive Therapeutics's PS Ratio
For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aquestive Therapeutics's PS Ratio Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Aquestive Therapeutics's PS Ratio falls into.
Aquestive Therapeutics PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Aquestive Therapeutics's Share Price of today is $4.07. Aquestive Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.78.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Aquestive Therapeutics (NAS:AQST) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Aquestive Therapeutics PS Ratio Related Terms
Thank you for viewing the detailed overview of Aquestive Therapeutics's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Aquestive Therapeutics (Aquestive Therapeutics) Business Description
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AQST has been successfully added to your 